ALK and non-small cell lung carcinoma: Access to plasma samples from ALK fusion positive NSCLC patients untreated with an ALK-TKI, with associated outcome data following drug administration, is a challenge and that made access to a validation cohort impossible, which is of course one of the main limitations of this study.